Trial intelligence / Profile preview

Phase III equivalence study of KM118 versus pertuzumab with trastuzumab and docetaxel as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer

CTR20230773Phase 3Active

Sponsor

China Resources Double-Crane Pharmaceutical

Start

Mar 2023

Modality

Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1